APA (7th ed.) Citation

GM, H., KV, K., PJ, T., B, E., B, H., C, V., . . . C, L. (2026). Phase II INTEGRIS-PSC trial of bexotegrast, an αvβ6/αvβ1 integrin inhibitor, in primary sclerosing cholangitis. Journal of hepatology, 84(1), 86. https://doi.org/10.1016/j.jhep.2025.09.016

Chicago Style (17th ed.) Citation

GM, Hirschfield, et al. "Phase II INTEGRIS-PSC Trial of Bexotegrast, an αvβ6/αvβ1 Integrin Inhibitor, in Primary Sclerosing Cholangitis." Journal of Hepatology 84, no. 1 (2026): 86. https://doi.org/10.1016/j.jhep.2025.09.016.

MLA (9th ed.) Citation

GM, Hirschfield, et al. "Phase II INTEGRIS-PSC Trial of Bexotegrast, an αvβ6/αvβ1 Integrin Inhibitor, in Primary Sclerosing Cholangitis." Journal of Hepatology, vol. 84, no. 1, 2026, p. 86, https://doi.org/10.1016/j.jhep.2025.09.016.